NCIt definition : A preparation of autologous human T-lymphocytes engineered to express dual chimeric
antigen receptors (CARs) consisting of both anti-CD19 and anti-CD22 binding domains,
fused to an as of yet undisclosed co-stimulatory domain, and linked to truncated forms
of the human epidermal growth factor receptor 2 (HER2t) and the human epidermal growth
factor receptor (EGFRt), respectively with potential immunostimulating and antineoplastic
activities. Upon administration, the autologous anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing
T-cells bind to CD19 and CD22 on the surface of, and induce selective toxicity against
tumor cells expressing CD19 and CD22. Devoid of both ligand binding domains and tyrosine
kinase activity, the expressed EGFRt and HER2t facilitate both in vivo detection of
the administered, transduced T-cells and can promote elimination of those cells through
an antibody-dependent cellular cytotoxicity (ADCC) response. CD19 and CD22, both transmembrane
phosphoglycoproteins expressed on the surface of cells in the B lineage, are often
overexpressed on malignant B-cells.;